RecruitingPhase 2NCT07050186
Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma
Studying NUT midline carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Northwestern University
- Principal Investigator
- Jochen H Lorch, MD, M.DNorthwestern University
- Intervention
- Biopsy Procedure(procedure)
- Enrollment
- 15 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2035
Study locations (1)
- Northwestern University, Chicago, Illinois, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07050186 on ClinicalTrials.govOther trials for NUT midline carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05372640Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid TumorsNational Cancer Institute (NCI)
- RECRUITINGNCT05265429Biology of Young Lung Cancer Study: The YOUNG LUNG StudyDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGNCT07459127Multicenter Retrospective Cohort of Pulmonary NUT CarcinomaThree Gorges Hospital of Chongqing University
- RECRUITINGPHASE1, PHASE2NCT05019716Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT CarcinomaNational Cancer Institute (NCI)